Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib. The stock is arguably expensive now, even with aggressive revenue estimates for 2031.

fool.com - 2026-07-07 06:15:00

Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 20:22:12

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 18:32:01

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

seekingalpha.com - 2026-05-29 17:24:06

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

seekingalpha.com - 2026-05-21 13:09:35

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

seekingalpha.com - 2026-05-20 18:20:55

Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.

marketbeat.com - 2026-05-20 10:08:42

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.

zacks.com - 2026-05-20 09:15:12

BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provided a business update.

globenewswire.com - 2026-05-20 07:00:00

Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-05-19 13:01:16

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 16:50:45

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update.

globenewswire.com - 2026-05-11 16:05:00

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m.

globenewswire.com - 2026-05-11 16:05:00

I believe my original bull case on Roivant Sciences has largely played out, with the stock up sharply since my initial coverage. Brepocitinib is clearly now becoming a broader immunology franchise across DM, NIU, CS, and LPP. ROIV also settled with Moderna regarding LNP, which adds to its already cash-rich balance sheet and supports its ongoing buybacks and pipeline.

seekingalpha.com - 2026-04-29 11:05:04

Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the

defenseworld.net - 2026-04-15 04:27:30